Dr. Dixon Discusses Making Mastectomy Decisions

Video

Dr. J. Michael Dixon, from the University of Edinburgh, Discusses Making the Decision to have a Mastectomy

J. Michael Dixon, MBChB, MD, Professor of Surgery, Consultant Surgeon, University of Edinburgh, Clinical Director of the Edinburgh Breast Unit, Western General Hospital, Edinburgh, Scotland, discusses the challenges facing patient choice in the mastectomy decision process.

Dixon explains that the common perception is that patient choice leads to better results, however, there is a lack of supporting evidence in the literature for this theory. In an examination of the decision making process it was found that when surgeons alone chose the treatment it resulted in approximately 5% of patients receiving mastectomy. In joint decisions, 15%-18% of patients received mastectomy and when patients chose nearly 30%-40% received mastectomy.

Women who face the choice of breast-conserving surgery over mastectomy are making the decision based on fear of cancer recurrence and death. However, Dixon notes, a significant different is not observed in a comparison between mastectomy and breast-conserving surgery.

The fear of recurrence appears to be primarily a US related issue. In a comparison, the number of women in the US having mastectomy is increasing while mastectomies in Europe are decreasing.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute